1.78 USD
▲-0.02+0.28%
盘后 1.78 +0.56%
2026-08-03
市值
$118.91M
市盈率
—
EPS
-2.12
股息率
—
52 周区间
1.40 – 12.25
成交量
640.75K
Beta
-0.28
目标价
3.29
52W 低 1.4052W 高 12.25
价格走势
公司简介
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based...